Dr. Zobair Younossi joins Roger Green to kick off our review coverage of TLM 2023. Dr. Younossi discusses the studies he presented at the meeting and discusses other work related to patient quality-of-life, economics of screening and treatment, and how stigma affects both patients and providers.
In this episode From the Vault, Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from the 2021 Paris NASH meeting, an event with exciting scientific messages and insights. This episode has played out to be by far the most downloaded segment in the podcast’s history!
Naim Alkhouri, Louise Campbell and Roger Green are joined by new guest, Prof. James O’Beirne, to discuss developing improved models for patient identification and risk stratification. Learning from past experiences with HCV, the LOCATE-NAFLD study was born and this episode dives into the project protocols, aims and potential takeaways.
Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss critical and/or compelling presentations and insights from the recently concluded EASL Congress in Vienna. The session focuses on new nomenclature and emerging stories around patient identification, NITs, fibrosis resolution and more.
Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA Scientific Sessions. In this conversation, Stephen expounds on newly released Phase 3 MAESTRO-NASH data on resmetirom with powerful notes around endpoints, the study population and other elements critical to the full trial package.
Surfing NASH conducted on-site coverage from EASL Congress 2023 in Vienna with Ian Rowe, Michael Betel, Jörn Schattenberg and Roger Green. In this conversation the group discusses a session that Jörn co-chaired on challenges in screening patients for fatty liver diseases. Notes touch on how time restrictions obstruct frontline treaters from offering both adequate screening and support lifestyle interventions simultaneously. The group goes on to consider the potential of dual agonists efinopegdutide and pemvidutide.
This final preview featuring the thoughts and anticipations of Louise Campbell and Roger Green explores the idea of harnessing technology to maximize the utility of databases in the effort of identifying patients.
This conversation covers final thoughts on the anticipations of Ian Rowe, Jörn Schattenberg and Roger Green heading into EASL Congress 2023. The group primarily explores a session on NAFLD clinical aspects which provides practical presentations around tools available now for treating and managing patients with NASH.
This conversation with Ian Rowe, Jörn Schattenberg and Roger Green begins to unpack the rich EASL Congress 2023 program and explore in detail presentations of interest. Specifically, the group dives into anticipations around an abstract session around diagnostics and non-invasive assessment.
This episode comprises three separate sessions as part of the Surfing NASH ongoing coverage of a highly anticipated EASL Congress 2023. The first two discussions feature Ian Rowe, Jörn Schattenberg, Louise Campbell and Roger Green as the group reviews their lists of abstracts to look forward to. Following is an extra-sode on the subject of AI and pathology with guests Arun Sanyal and David Kleiner.
